Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2010-023935-41-ES
EUCTR2010-023935-41-ES
Active, not recruiting
Not Applicable

PILOT STUDY ASSESSING THE EFFECTIVENESS OF 18FDG PET-CT IN THE EARLY DIAGNOSIS OF BREAST CANCER AND / OR OVARIAN CANCER IN WOMEN BRCA1 or BRCA 2 MUTATION CARRIERS

Consorcio de Apoyo a la Investigación Biomédica en Red (CAIBER)0 sites234 target enrollmentApril 12, 2012
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsBreast cancer screening in women BRCA1 or BRCA2 mutation.Therapeutic area: Diseases [C] - Cancer [C04]
DrugsFludesoxiglucosa

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Breast cancer screening in women BRCA1 or BRCA2 mutation.
Sponsor
Consorcio de Apoyo a la Investigación Biomédica en Red (CAIBER)
Enrollment
234
Status
Active, not recruiting
Last Updated
14 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 12, 2012
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
Female

Investigators

Sponsor
Consorcio de Apoyo a la Investigación Biomédica en Red (CAIBER)

Eligibility Criteria

Inclusion Criteria

  • •1\.\- Mujeres mayores de 18 años.
  • •2\.\- No diagnosticadas de cáncer previo a su entrada en el estudio.
  • •3\.\- Portadoras de alguna mutación patogénica en los genes BRCA1 o 2\.
  • •4\.\- No existir contraindicación para la realización de PET\-TAC con 18FDG o alguna de las pruebas habituales de seguimiento programadas para su grupo de riesgo.
  • •5\.\- Haber firmado el consentimiento informado.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range 230
  • •F.1\.3 Elderly (\>\=65 years) yes

Exclusion Criteria

  • •1\.\- Haber sido diagnosticadas de algún cáncer previo a la entrada en el estudio.
  • •2\.\- Ser menor de 18 años.
  • •3\.\- Haberse sometido a algún tipo de cirugía preventiva a nivel mamario y/u ovárico previo a su entrada en el estudio.
  • •4\.\- No cumplir alguno de los criterios de inclusión.
  • •5\.\- Uso de metformina.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
To evaluate and compare the efficacy of 18F-FDG PET taken in hyperglycemic state, 18F-FDG PET taken in NPO state, and C-11 acetate PET in detecting and grading brain tumorNeoplasms
KCT0004466Yonsei University Health System, Severance Hospital73
Active, not recruiting
Phase 1
Experimental study to evaluate the effect of PET/TC using 18F-PSMA label in the management of patients with prostate cancer.Prostate cancerMedDRA version: 20.0Level: LLTClassification code 10029002Term: Neoplasm of the prostateSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2019-002000-41-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS500
Recruiting
Not Applicable
Clinical study to evaluate the usefulness of 18F-FBPA-PET for patient selection and expanding indication for BNCTHead and Neck Cancer,Malignant glioma
JPRN-UMIN000035976Southern TOHOKU BNCT Research Center20
Active, not recruiting
Phase 1
Domestic Phase I/IIa Investigator-initiated Clinical Trials to Evaluate the Safety of 18F-PSMA-1007 in Healthy Adults and Subjects with Prostate Cancer
JPRN-jRCT2032210711Tateishi Ukihide13
Active, not recruiting
Phase 1
A Pilot Study Investigating the Sensitivity of 18F-labelled Sodium Fluoride PET-CT for Detecting Skeletal Metastases in Renal Cell Carcinoma compared to Planar Bone Scintigraphy and Multidetector CT - 18F-Fluoride PET-CT for Detecting Bone Metastases in RCC
EUCTR2010-024624-20-GBCambridge University Hospitals NHS Foundation Trust and University of Cambridge